Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 safety and PK/PD study of C21 in idiopathic pulmonary fibrosis
2017-004923-63Phase 2Terminated
- Sponsor
- Vicore Pharma
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing C21 with Placebo (2 arms). Primary endpoint: Incidence of Adverse Events. Started Dec 2017; status: terminated.
02
Drugs
buloxibutid
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2017-004923-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004923-63.